Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave Research Published on 2022-07-152022-10-05 Journal: British Journal of Cancer [Category] 임상, 치료법, [키워드] anticancer cancer patient cancer treatment Characteristics Chemotherapy Clinical outcome combination therapy Comprehensive COVID COVID-19 COVID-19 infection COVID-19-related death evaluated First wave hospital Immunotherapy measure outcome pandemic Patient paucity of data positive proportion Radical receive receiving reduced reported Result risk SACT Safe Support therapy treated Treatment [DOI] 10.1038/s41416-022-01909-0 [Article Type] Research
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of NirmatrelvirNirmatrelvir의 잠재적인 SARS-CoV-2 회피에 대한 진화적 및 구조적 통찰력Review Published on 2022-07-142022-09-11 Journal: Journal of medicinal chemistry [Category] COVID19(2023년), SARS, 변종, [키워드] Analysis analyzed antibody approval arises broad-spectrum antiviral broad-spectrum antivirals combination therapy COVID-19 pandemic drug-resistant indicate inhibitor insight M pro Mutation Nirmatrelvir Paxlovid Potential Pro protease residue residues Ritonavir SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants significantly U.S. FDA Vaccine Viral resistance viral variant [DOI] 10.1021/acs.jmedchem.2c00404 PMC 바로가기 [Article Type] Review
COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case ReportHCV 감염 및 대상성 간경변증에 대한 직접 작용 항바이러스제 치료 후 COVID-19: 증례 보고Case Reports Published on 2022-07-012022-09-11 Journal: In vivo (Athens, Greece) [Category] 치료제, [키워드] Admission Cardiac arrest cirrhosis Combination combination therapy combination treatment coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia decompensated cirrhosis. diagnosed direct-acting antiviral Direct-acting antivirals discharge discharged eradication Exacerbation HCV hepatitis C hepatitis C virus hospital immunological changes IMPROVE individuals infected individuals Infection inhibitor interferon Liver function long term male NS5A NS5B occurred Occurrence Patient performed Pneumonia polymerase Prevent report RNA SARS-CoV-2 severe COVID-19 sofosbuvir sustained SVR the patient Treatment undetectable velpatasvir virological response with COVID-19 [DOI] 10.21873/invivo.12923 PMC 바로가기 [Article Type] Case Reports
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, [키워드] Adverse adverse event adverse events Antiviral Antiviral agents clinical Combination combination regimen combination therapy COVID-19 Day demonstrated Efficacy Efficacy and safety event examined Favipiravir FVP group groups hospital ICU admission ill patient in-hospital mortality incidence interferon Interferon-beta IQR LOS median Mild not different not significantly different Patient Potential treatment primary endpoint randomization Randomized randomized clinical trial Randomly receive Registered registry SARS-coronavirus SARS-CoV-2 Seven single-center Treatment treatment regimen Trial viral clearance [DOI] 10.1002/jmv.27724 PMC 바로가기 [Article Type] Randomized Controlled Trial
Early combination therapy with immunoglobulin and steroids is associated with shorter ICU length of stay in Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19: A retrospective cohort analysis from 28 U.S. Hospitals면역글로불린과 스테로이드를 사용한 조기 병용 요법은 COVID-19와 관련된 소아 다기관 염증 증후군(MIS-C)의 ICU 체류 기간 단축과 관련이 있습니다. 28개 미국 병원의 후향적 코호트 분석Article Published on 2022-07-012022-09-12 Journal: Pharmacotherapy [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adjustment Admission Analysis analyzed benefit children with MIS-C Combination combination therapy confidence interval confounder confounders Corticosteroids COVID-19 Day Fever hospital Hospitalization hospitalized patient ICU illness Immunoglobulin Impact include inflammatory mediator initiated intensive care Intravenous immunoglobulin IQR IVIG LOS median age Medicine MIS-C Mortality multivariable organ dysfunction outcomes Patient random intercept registry required respiratory retrospective cohort Retrospective study secondary outcome shown significant decrease significant difference Society steroid Steroids study population The United States therapeutic option therapy total patients Universal [DOI] 10.1002/phar.2709 PMC 바로가기 [Article Type] Article
Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variantsCorrespondence Published on 2022-07-012022-10-05 Journal: The Journal of Infection [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] antiviral drug antiviral therapy Aprotinin combination therapy COVID-19 interferon Interferon-beta molnupiravir Nirmatrelvir Remdesivir SARS-CoV-2 SARS-CoV-2 variant [DOI] 10.1016/j.jinf.2022.07.023 [Article Type] Correspondence
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens Research Published on 2022-06-302022-10-05 Journal: NPJ Digital Medicine [Category] 신약개발, 임상, 치료법, 치료제, [키워드] adjusted B.1.351 B.1.617.2 Beta candidate drug clinically clinician combination regimen combination therapy combinations Community COVID-19 Delta drug combination Drug interactions Efficacy EIDD-1931 experimental validation Infectious disease Live virus pandemic platform Rapid regimen representing SARS-CoV-2 SARS-CoV-2 variant therapy translation Vero E6 was used [DOI] 10.1038/s41746-022-00627-4 [Article Type] Research
Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: a retrospective studyObservational Study Published on 2022-06-282022-10-04 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] Antibiotics Antigen Antiviral chest X-ray clinically combination therapy conducted cough COVID-19 COVID-19 pandemic discharged home Diseases Dyspnoea Epidemiology Final First wave greater handling hospital hospitalisation Hydroxychloroquine incidence Infection Infectious diseases laboratory characteristics Laboratory parameters Length mechanical ventilation Mortality Nasopharyngeal swab Negative PCR outcome pandemic Patient patients with COVID-19 peripheral oxygen saturation Pneumonia positive COVID-19 Real-time PCR required respiratory rate retrospective Retrospective study SARS-COV-2 infection second second wave secondary care significantly higher Steroids supplemental oxygen Symptom the patient were excluded [DOI] 10.1136/bmjopen-2022-061610 PMC 바로가기 [Article Type] Observational Study
Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trialResearch article Published on 2022-06-032022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, 치료제, [키워드] 95% CI Admission Adverse AMED assigned calculated camostat Characteristics Ciclesonide clinical Clinical finding Clinical management Combination combination therapy comparable COVID-19 COVID-19 infection deaths decrease development discharge Effectiveness enrolled evaluated event Favipiravir finding funding group groups healthcare worker hospital discharge rate Hospital stay Hospitalization Hospitalized Japan Japanese lack less limitation median time Ministry of Health monotherapy no significant difference number Open-label oxygen participant Patient patients patients with moderate Phase 3 phase 3 study Pneumonia positive Primary outcome randomized clinical trial Randomized controlled trial Randomly Registered registry Research SARS-CoV-2 Severe COVID-19 Infection significantly higher significantly lower single-center statistically supported therapy Treatment vaccination Version Welfare [DOI] 10.1016/j.eclinm.2022.101484 [Article Type] Research article
Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy루틴 기반 조합 요법을 사용하여 SARS-CoV-2 감염에 대한 유망한 치료 접근 방식Article Published on 2022-06-032022-09-11 Journal: ChemMedChem [Category] COVID19(2023년), SARS, 치료제, [키워드] Acetylsalicylic acid addition Administered antioxidants Antiviral Antiviral agents Bacterial calcium combating combination therapy components compounds described early stage early stages flavonoids host cell indication Infection inhibit Magnesium molecular molecular recognition natural natural products noncovalent interactions offer prophylactically provide rutin Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections severe disease progression targets Therapeutic approach therapy viruses Vitamin C Vitamin D vitamins [DOI] 10.1002/cmdc.202200157 PMC 바로가기 [Article Type] Article